ALLURION TECHNOLOGIES, INC. 8-K

What Happened
Allurion Technologies, Inc. (ALUR) filed a Form 8-K on February 23, 2026, announcing that the U.S. Food and Drug Administration (FDA) granted Premarket Approval (PMA) for the Allurion Gastric Balloon system, which includes the Allurion Smart Capsule. The device is approved for treatment of adults aged 22–65 years with obesity (BMI ≥ 30 kg/m2 and ≤ 40 kg/m2) who have had at least one unsuccessful weight-loss attempt. The company attached a press release dated February 23, 2026, as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: February 23, 2026 (Form 8-K, Item 7.01, Item 9.01 exhibits).
• Approval type: FDA Premarket Approval (PMA) for the Allurion Gastric Balloon system.
• Indicated population: Adults 22–65 years old with BMI ≥ 30 and ≤ 40 kg/m2, after at least one unsuccessful weight-loss program.
• Press release referenced: Exhibit 99.1 to the Current Report on Form 8-K.

Why It Matters
FDA PMA is a major regulatory milestone that clears the Allurion Gastric Balloon system for commercial use in the United States for a defined patient population. For investors, this reduces a key regulatory barrier and could enable U.S. market commercialization and revenue opportunities tied to the device; it also clarifies the approved patient population and regulatory status. The 8-K is a factual disclosure of the approval and related press release; it does not include financial forecasts or commercialization timelines.